oa FAME 2 – The best initial strategy for patients with stable coronary artery disease: Do we have an answer at last?

References

1. B De Bruyne, NHJ Pijls, B Kalesan, et al.. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med.. 2012; 367::991–1001
   [Google Scholar]
2. WE Boden, RA O'Rourke, KK Teo, et al.. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356::1503–16
   [Google Scholar]
3. MR Patel, GJ Dehmer, JW Hirshfeld, PK Smith, JA Spertus. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA.SCCT Appropriate use criteria for coronary revascularization focused update. A report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American, Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2012; 59::857–81
   [Google Scholar]
4. W Wijns, P Kolh, N Danchin, et al.. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010; 31::2501–55
   [Google Scholar]
5. RO Bonow. Guidelines for revascularization: the evidence base matures. Global Cardiology Science and Practice. 2012; 19:http://dx.doi.org/10.5339/gcsp.2012.19
   [Google Scholar]
6. Fearon, W. FFR-guided PCI demonstrates cost-effectiveness when compared to medical therapy for stable coronary artery disease. available at < http://www.tctmd.com/show.aspx?id = 115792>
7. LJ Shaw, DS Berman, DJ Maron, et al.. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008; 117::1283–1291
   [Google Scholar]